– XPOVIO® is the first XPO1 inhibitor approved for reimbursement by South Korea’s National Health Insurance Service (NHIS) for the treatment of adult patients with relapsed/refractory multiple myeloma (R/R MM). – The approval of XPOVIO® by the NHIS in South Korea is the fourth national…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.